These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 2983321)

  • 41. Synthetic peptides against foot-and-mouth disease--immunization with VP1-peptides of type O1-Kaufbeuren.
    Liebermann H; Holl U; Reimann I; Nöckler A; Schäfer D; Thalmann G; Dölling R
    Arch Exp Veterinarmed; 1990; 44(6):883-90. PubMed ID: 1966360
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antigenic regions of poliovirus type 3/Sabin capsid proteins recognized by human sera in the peptide scanning technique.
    Roivainen M; Närvänen A; Korkolainen M; Huhtala ML; Hovi T
    Virology; 1991 Jan; 180(1):99-107. PubMed ID: 1701949
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Conformational constraints of conserved neutralizing epitopes from a major antigenic area of human respiratory syncytial virus fusion glycoprotein.
    López JA; Andreu D; Carreño C; Whyte P; Taylor G; Melero JA
    J Gen Virol; 1993 Dec; 74 ( Pt 12)():2567-77. PubMed ID: 7506298
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mapping of antigenic domains in poliovirus VP1 involved in structural rearrangements during virus morphogenesis and antigenic alterations of the virion.
    Ketterlinus R; Wiegers K
    Virology; 1994 Oct; 204(1):27-37. PubMed ID: 7522372
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neutralizing epitopes of type O foot-and-mouth disease virus. II. Mapping three conformational sites with synthetic peptide reagents.
    Parry NR; Barnett PV; Ouldridge EJ; Rowlands DJ; Brown F
    J Gen Virol; 1989 Jun; 70 ( Pt 6)():1493-503. PubMed ID: 2471812
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chemical cleavage of polyomavirus major structural protein VP1: identification of cleavage products and evidence that the receptor moiety resides in the carboxy-terminal region.
    Anders DG; Consigli RA
    J Virol; 1983 Oct; 48(1):197-205. PubMed ID: 6310143
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cell-induced conformational change in poliovirus: externalization of the amino terminus of VP1 is responsible for liposome binding.
    Fricks CE; Hogle JM
    J Virol; 1990 May; 64(5):1934-45. PubMed ID: 2157861
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Location of an immunizing determinant within polypeptide VP1 of type O aphthovirus.
    Haresnape JM; King AM; McCahon D
    J Gen Virol; 1983 Nov; 64 (Pt 11)():2357-65. PubMed ID: 6196439
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Characterization and specificity of humoral immune responses to Theiler's murine encephalomyelitis virus capsid proteins.
    Clatch RJ; Pevear DC; Rozhon E; Roos RP; Miller SD; Lipton HL
    J Gen Virol; 1987 Dec; 68 ( Pt 12)():3191-6. PubMed ID: 2826657
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chemically synthesized peptides elicit neutralizing antibody to bovine enterovirus.
    Smyth MS; Hoey EM; Trudgett A; Martin SJ; Brown F
    J Gen Virol; 1990 Jan; 71 ( Pt 1)():231-4. PubMed ID: 1689368
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Peptide antisera targeted to a conserved sequence in poliovirus capsid VP1 cross-react widely with members of the genus Enterovirus.
    Hovi T; Roivainen M
    J Clin Microbiol; 1993 May; 31(5):1083-7. PubMed ID: 8388885
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antigenic analysis of poliovirus type 3 using monoclonal antibodies.
    Ferguson M; Minor PD; Magrath DI; Schild GC
    Dev Biol Stand; 1984; 57():151-5. PubMed ID: 6098495
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The potential of retro-inverso peptides as synthetic vaccines.
    Van Regenmortel MH; Guichard G; Benkirane N; Briand JP; Muller S; Brown F
    Dev Biol Stand; 1998; 92():139-43. PubMed ID: 9554267
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Binding of neutralizing monoclonal antibodies to regions of the fusion protein of respiratory syncytial virus expressed in Escherichia coli.
    Lounsbach GR; Bourgeois C; West WH; Robinson JW; Carter MJ; Toms GL
    J Gen Virol; 1993 Dec; 74 ( Pt 12)():2559-65. PubMed ID: 7506297
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antigenic and structural relatedness among non-capsid and capsid polypeptides of polioviruses belonging to different serotypes.
    Romanova LI; Tolskaya EA; Agol VI
    J Gen Virol; 1981 Feb; 52(Pt 2):279-89. PubMed ID: 6169783
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Isolation of escape mutants of a hybrid poliovirus with the aid of insert-specific polyclonal antibodies.
    Hovi T; Huovilainen A; Murdin A; Wimmer E
    J Gen Virol; 1995 Jul; 76 ( Pt 7)():1861-5. PubMed ID: 9049393
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A high proportion of anti-peptide antibodies recognize foot-and-mouth disease virus particles.
    Parry NR; Syred A; Rowlands DJ; Brown F
    Immunology; 1988 Aug; 64(4):567-72. PubMed ID: 2844657
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunogenicity of enterovirus 70 capsid protein VP1 and its non-overlapping N- and C-terminal fragments.
    Chen D; Duggan C; Texada DE; Reden TB; Kooragayala LM; Langford MP
    Antiviral Res; 2005 Jun; 66(2-3):111-7. PubMed ID: 15911028
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intertypic cross-reactions of nonneutralizing, monoclonal poliovirus antibodies.
    Vrijsen R; Rombaut B; Boeye A
    J Virol; 1984 Mar; 49(3):1002-4. PubMed ID: 6199509
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Application of monoclonal antibodies for the identification of the antigenic site for poliovirus neutralization.
    Minor PD; Schild GC; Evans D; Ferguson M; Almond J
    Dev Biol Stand; 1984; 57():171-5. PubMed ID: 6084608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.